Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Schlößer, Hans A ^a   Drebber, Uta ^a   Kloth, Michael ^a   Thelen, Martin ^a   Rothschild, Sacha I ^a,b   Haase, Simon ^a   Garcia Marquez, Maria ^a   Wennhold, Kerstin ^a   Berlth, Felix ^a   Urbanski, Alexander ^a   Alakus, Hakan ^a   Schauss, Astrid ^a   Shimabukuro Vornhagen, Alexander ^a   Theurich, Sebastian ^a,c   Warnecke Ebertz, Ute ^a   Stippel, Dirk L ^a   Zippelius, Alfred ^b   Büttner, Reinhard ^a   Hallek, Michael ^a   Hölscher, Arnulf H ^a   Zander, Thomas ^a   Mönig, Stefan P ^a   von Bergwelt Baildon, Michael ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Checkpoint inhibitors; CTLA 4; Gastric cancer; Immunotherapy; PD 1; PD L1; Tumor infiltrating lymphocytes

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SOMATIC MUTATION; STOMACH ADENOCARCINOMA; TOTAL STOMACH RESECTION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84975886587     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1100789     Document Type: Article

References (56)

1. M.Song, D.Kang, J.J.Yang, J.-Y.Choi, H.Sung, Y.Lee, H.-S.Yoon, Y.Choi, S.-H.Kong, H.-J.Lee et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer 2015 Jul; 18(3):580-9; PMID:25091081; http://dx.doi.org/10.1007/s10120-014-0411-x.
2. D.Cunningham, W.H.Allum, S.P.Stenning, J.N.Thompson, C.J.H.Van de Velde, M.Nicolson, J.H.Scarffe, F.J.Lofts, S.J.Falk, T.J.Iveson et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20; PMID:16822992; http://dx.doi.org/10.1056/NEJMoa055531
3. Y.-J.Bang, E.Van Cutsem, A.Feyereislova, H.C.Chung, L.Shen, A.Sawaki, F.Lordick, A.Ohtsu, Y.Omuro, T.Satoh et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97; PMID:20728210; http://dx.doi.org/10.1016/S0140-6736(10)61121-X
4. O.Nakano, M.Sato, Y.Naito, K.Suzuki, S.Orikasa, M.Aizawa, Y.Suzuki, I.Shintaku, H.Nagura, H.Ohtani. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6; PMID:11431351
5. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pagès, M.Tosolini, M.Camus, A.Berger, P.Wind et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
6. H.E.Lee, S.W.Chae, Y.J.Lee, M.A.Kim, H.S.Lee, B.L.Lee, W.H.Kim. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008; 99:1704-11; PMID:18941457; http://dx.doi.org/10.1038/sj.bjc.6604738
7. + memory T cells on human gastric cancer. Oncol Rep 2013; 29:1756-62; PMID:23440298; http://dx.doi.org/10.3892/or.2013.2302
8. S.Turcotte, A.Gros, E.Tran, C.-C.R.Lee, J.R.Wunderlich, P.F.Robbins, S.A.Rosenberg. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res 2014; 20:331-43; PMID:24218514; http://dx.doi.org/10.1158/1078-0432.CCR-13-1736
9. H.A.Schlößer, S.Theurich, A.Shimabukuro-Vornhagen, U.Holtick, D.L.Stippel, M.von Bergwelt-Baildon. Overcoming tumor-mediated immunosuppression. Immunotherapy 2014; 6:973-88; PMID:25341119; http://dx.doi.org/10.2217/imt.14.58
10. D.M.Pardoll. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012; 13:1129-32; PMID:23160205; http://dx.doi.org/10.1038/ni.2392
11. A.H.Sharpe, E.J.Wherry, R.Ahmed, G.J.Freeman. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-45; PMID:17304234; http://dx.doi.org/10.1038/ni1443
12. H.Dong, S.E.Strome, D.R.Salomao, H.Tamura, F.Hirano, D.B.Flies, P.C.Roche, J.Lu, G.Zhu, K.Tamada et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
13. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
14. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.-J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
15. J.R.Brahmer, S.S.Tykodi, L.Q.M.Chow, W.-J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
16. J.R.Brahmer, C.G.Drake, I.Wollner, J.D.Powderly, J.Picus, W.H.Sharfman, E.Stankevich, A.Pons, T.M.Salay, T.L.McMiller et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
17. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
18. Y.Ohigashi, M.Sho, Y.Yamada, Y.Tsurui, K.Hamada, N.Ikeda, T.Mizuno, H.Kashizuka, K.Yane, F.Tsushima et al. Clinical Significance of Programmed Death-1Ligand-1 and Programmed Death-1Ligand-2 Expression in Human Esophageal Cancer. 2005; 11:2947-53; PMID:15837746; http://dx.doi.org/10.1158/1078-0432.CCR-04-1469
19. Q.Gao, X.-Y.Wang, S.-J.Qiu, I.Yamato, M.Sho, Y.Nakajima, J.Zhou, B.-Z.Li, Y.-H.Shi, Y.-S.Xiao et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15:971-9; PMID:19188168; http://dx.doi.org/10.1158/1078-0432.CCR-08-1608
20. J.Hamanishi, M.Mandai, M.Iwasaki, T.Okazaki, Y.Tanaka, K.Yamaguchi, T.Higuchi, H.Yagi, K.Takakura, N.Minato et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:3360-5; PMID:17360651; http://dx.doi.org/10.1073/pnas.0611533104
21. R.H.Thompson, S.M.Kuntz, B.C.Leibovich, H.Dong, C.M.Lohse, W.S.Webster, S.Sengupta, I.Frank, A.S.Parker, H.Zincke et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381-5; PMID:16585157; http://dx.doi.org/10.1158/0008-5472.CAN-05-4303
22. J.W.Kim, K.H.Nam, S.-H.Ahn, D.J.Park, H.-H.Kim, S.H.Kim, H.Chang, J.-O.Lee, Y.J.Kim, H.S.Lee et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 2016 Jan; 19(1):42-52; PMID:25424150; http://dx.doi.org/10.1007/s10120-014-0440-5
23. C.Wu, Y.Zhu, J.Jiang, J.Zhao, X.-G.Zhang, N.Xu. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006; 108:19-24; PMID:16530813; http://dx.doi.org/10.1016/j.acthis.2006.01.003
24. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, M D JW, C.Garbe, C.Lebbe, J.-F.Baurain, A.Testori, J.-J.Grob et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
25. L.S.K.Walker, D.M.Sansom. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852-63; PMID:22116087; http://dx.doi.org/10.1038/nri3108
26. S.Salvi, V.Fontana, S.Boccardo, D.F.Merlo, E.Margallo, S.Laurent, A.Morabito, E.Rijavec, M.G.Dal Bello, M.Mora et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother 2012; 61:1463-72; PMID:22318401; http://dx.doi.org/10.1007/s00262-012-1211-y
27. H.Mao, L.Zhang, Y.Yang, W.Zuo, Y.Bi, W.Gao, B.Deng, J.Sun, Q.Shao, X.Qu. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 2010; 10:728-36; PMID:20578982; http://dx.doi.org/10.2174/156800910793605811
28. E.Contardi, G.L.Palmisano, P.L.Tazzari, A.M.Martelli, F.Falà, M.Fabbi, T.Kato, E.Lucarelli, D.Donati, L.Polito et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005; 117:538-50; PMID:15912538; http://dx.doi.org/10.1002/ijc.21155
29. S.Laurent, P.Queirolo, S.Boero, S.Salvi, P.Piccioli, S.Boccardo, S.Minghelli, A.Morabito, V.Fontana, G.Pietra et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 2013; 11:108; PMID:23634660; http://dx.doi.org/10.1186/1479-5876-11-108
30. C.Ralph, E.Elkord, D.J.Burt, J.F.O'Dwyer, E.B.Austin, P.L.Stern, R.E.Hawkins, F.C.Thistlethwaite. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010; 16:1662-72; PMID:20179239; http://dx.doi.org/10.1158/1078-0432.CCR-09-2870
31. M.Kloth, V.Ruesseler, C.Engel, K.Koenig, M.Peifer, E.Mariotti, H.Kuenstlinger, A.Florin, U.Rommerscheidt-Fuss, U.Koitzsch et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 2015; PMID:26001389; http://dx.doi.org/10.1136/gutjnl-2014-309026
32. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.-J.Hwu, T.C.Gangadhar et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
33. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
34. S.J.Lin, J.A.Gagnon-Bartsch, I.B.Tan, S.Earle, L.Ruff, K.Pettinger, B.Ylstra, N.van Grieken, S.Y.Rha, H.C.Chung et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 2015 Nov; 64(11):1721-31; PMID:25385008; http://dx.doi.org/10.1136/gutjnl-2014-308252
35. M.Ahmadzadeh, L.A.Johnson, B.Heemskerk, J.R.Wunderlich, M.E.Dudley, D.E.White, S.A.Rosenberg. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792
36. M.Terme, E.Ullrich, L.Aymeric, K.Meinhardt, M.Desbois, N.Delahaye, S.Viaud, B.Ryffel, H.Yagita, G.Kaplanski et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71:5393-9; PMID:21724589; http://dx.doi.org/10.1158/0008-5472.CAN-11-0993
37. K.Titanji, V.Velu, L.Chennareddi, M.Vijay-Kumar, A.T.Gewirtz, G.J.Freeman, R.R.Amara. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest 2010; 120:3878-90; PMID:20972331; http://dx.doi.org/10.1172/JCI43271
38. + T cells. Eur J Immunol 2012; 42:662-71; PMID:22144176; http://dx.doi.org/10.1002/eji.201141931
39. H.Krönig, K.Julia Falchner, M.Odendahl, B.Brackertz, H.Conrad, D.Muck, R.Hein, C.Blank, C.Peschel, B.Haller et al. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. Int J Cancer 2012; 130:2327-36; PMID:21717461; http://dx.doi.org/10.1002/ijc.26272
40. M.Quigley, F.Pereyra, B.Nilsson, F.Porichis, C.Fonseca, Q.Eichbaum, B.Julg, J.L.Jesneck, K.Brosnahan, S.Imam et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010; 16:1147-51; PMID:20890291; http://dx.doi.org/10.1038/nm.2232
41. C.Badoual, S.Hans, N.Merillon, C.Van Ryswick, P.Ravel, N.Benhamouda, E.Levionnois, M.Nizard, A.Si-Mohamed, N.Besnier et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
42. S.A.Quezada, K.S.Peggs, M.A.Curran, J.P.Allison. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-45; PMID:16778987; http://dx.doi.org/10.1172/JCI27745
43. J.Duraiswamy, K.M.Kaluza, G.J.Freeman, G.Coukos. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73:3591-603; PMID:23633484; http://dx.doi.org/10.1158/0008-5472.CAN-12-4100
44. H.Chen, C.I.Liakou, A.Kamat, C.Pettaway, J.F.Ward, D.N.Tang, J.Sun, A.A.Jungbluth, P.Troncoso, C.Logothetis et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 2009; 106:2729-34; PMID:19202079; http://dx.doi.org/10.1073/pnas.0813175106
45. C.I.Liakou, A.Kamat, D.N.Tang, H.Chen, J.Sun, P.Troncoso, C.Logothetis, P.Sharma. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105:14987-92; PMID:18818309; http://dx.doi.org/10.1073/pnas.0806075105
46. G.Perrone, P.A.Ruffini, V.Catalano, C.Spino, D.Santini, P.Muretto, C.Spoto, C.Zingaretti, V.Sisti, P.Alessandroni et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44:1875-82; PMID:18617393; http://dx.doi.org/10.1016/j.ejca.2008.05.017
47. Z.Shen, S.Zhou, Y.Wang, R.Li, C.Zhong, C.Liang, Y.Sun. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 2010; 136:1585-95; PMID:20221835; http://dx.doi.org/10.1007/s00432-010-0816-9
48. H.-I.Kim, H.Kim, H.W.Cho, S.Y.Kim, K.J.Song, W.J.Hyung, C.-G.Park, C.-B.Kim. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. J Surg Oncol 2011; 104:728-33; PMID:21792941; http://dx.doi.org/10.1002/jso.22038
49. S.Kashimura, Z.Saze, M.Terashima, N.Soeta, S.Ohtani, F.Osuka, M.Kogure, M.Gotoh. CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer. Gastric Cancer 2012; 15:144-53; PMID:22083420; http://dx.doi.org/10.1007/s10120-011-0090-9
50. S.Zhou, Z.Shen, Y.Wang, H.Ma, S.Xu, J.Qin, L.Chen, H.Tao, Z.Zhen, G.Chen et al. CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One 2013; 8:e74430; PMID:24040244; http://dx.doi.org/10.1371/journal.pone.0074430
51. F.A.Sinicrope, R.L.Rego, S.M.Ansell, K.L.Knutson, N.R.Foster, D.J.Sargent. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137:1270-9; PMID:19577568; http://dx.doi.org/10.1053/j.gastro.2009.06.053
52. E.Krystufkova, A.Sekerkova, I.Striz, I.Brabcova, E.Girmanova, O.Viklicky. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant 2012; 27:2576-82; PMID:22167587; http://dx.doi.org/10.1093/ndt/gfr693
53. Y.Ino, R.Yamazaki-Itoh, K.Shimada, M.Iwasaki, T.Kosuge, Y.Kanai, N.Hiraoka. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013; 108:914-23; PMID:23385730; http://dx.doi.org/10.1038/bjc.2013.32
54. S.Kim, J.Lee, M.E.Hong, I.-G.Do, S.Y.Kang, S.Y.Ha, S.T.Kim, S.H.Park, W.K.Kang, M.-G.Choi et al. High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One 2014; 9:e111693; PMID:25372287; http://dx.doi.org/10.1371/journal.pone.0111693
55. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-) 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
56. E.J.Lipson, W.H.Sharfman, C.G.Drake, I.Wollner, J.M.Taube, R.A.Anders, H.Xu, S.Yao, A.Pons, L.Chen et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462-8; PMID:23169436; http://dx.doi.org/10.1158/1078-0432.CCR-12-2625